Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
NCT04229004Phase 3Completed
- Sponsor
- Pancreatic Cancer Action Network
- Start
- Jan 2020
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pamrevlumab, canakinumab, spartalizumab, racemetyrosine in pancreatic adenocarcinoma (PDAC), sponsored by Pancreatic Cancer Action Network. Started Jan 2020; status: completed.
02
Drugs
pamrevlumabcanakinumabspartalizumabracemetyrosine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04229004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229004.